G Dieplinger1, M J Everly1, K P Briley2, C E Haisch3, P Bolin4, A Q Maldonado5, W T Kendrick6, S A Kendrick6, C Morgan3, P I Terasaki1, L M Rebellato2. 1. Terasaki Research Institute, Los Angeles, California, USA. 2. Department of Pathology, Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA. 3. Department of Surgery, Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA. 4. Department of Medicine, Brody School of Medicine at East Carolina University, Greenville, North Carolina, USA. 5. Vidant Medical Center, Greenville, North Carolina, USA. 6. Eastern Nephrology Associates, Greenville, North Carolina, USA.
Abstract
BACKGROUND: BK polyomavirus (BKPyV) viremia/nephropathy and reduction in immunosuppression following viremia may increase the risk of alloimmune activation and allograft rejection. This study investigates the impact of BKPyV viremia on de novo donor anti-human leukocyte antigen (HLA)-specific antibodies (dnDSA). PATIENTS AND METHODS: All primary renal transplants at East Carolina University from March 1999 to December 2010, with at least 1 post-transplant BKPyV viral load testing, were analyzed. Patients were negative for anti-HLA antibodies to donor antigens (tested via single antigen beads) at transplantation and at first BKPyV testing. RESULTS: Nineteen of 174 patients (11%) tested positive for BKPyV viremia. Within 24 months of BKPyV viremia detection, 79% of BKPyV-viremic patients developed dnDSA. Only 20% of BKPyV viremia-persistent cases, compared to 86% of BKPyV viremia-resolved cases, developed dnDSA (P = 0.03). Poor allograft survival was evident in BKPyV viremia-persistent patients (60% failure by 2 years post BKPyV diagnosis) and in BKPyV viremia-resolved patients with dnDSA (5-year post BKPyV diagnosis allograft survival of 48%). CONCLUSIONS: Post-transplant BKPyV viremia and preemptive immunosuppression reduction is associated with high rates of dnDSA. When preemptively treating BKPyV viremia, dnDSA should be monitored to prevent allograft consequences.
BACKGROUND:BK polyomavirus (BKPyV) viremia/nephropathy and reduction in immunosuppression following viremia may increase the risk of alloimmune activation and allograft rejection. This study investigates the impact of BKPyVviremia on de novo donor anti-human leukocyte antigen (HLA)-specific antibodies (dnDSA). PATIENTS AND METHODS: All primary renal transplants at East Carolina University from March 1999 to December 2010, with at least 1 post-transplant BKPyV viral load testing, were analyzed. Patients were negative for anti-HLA antibodies to donor antigens (tested via single antigen beads) at transplantation and at first BKPyV testing. RESULTS: Nineteen of 174 patients (11%) tested positive for BKPyVviremia. Within 24 months of BKPyVviremia detection, 79% of BKPyV-viremic patients developed dnDSA. Only 20% of BKPyVviremia-persistent cases, compared to 86% of BKPyVviremia-resolved cases, developed dnDSA (P = 0.03). Poor allograft survival was evident in BKPyVviremia-persistent patients (60% failure by 2 years post BKPyV diagnosis) and in BKPyVviremia-resolved patients with dnDSA (5-year post BKPyV diagnosis allograft survival of 48%). CONCLUSIONS: Post-transplant BKPyVviremia and preemptive immunosuppression reduction is associated with high rates of dnDSA. When preemptively treating BKPyVviremia, dnDSA should be monitored to prevent allograft consequences.
Authors: Carrie A Schinstock; Darshana M Dadhania; Matthew J Everly; Byron Smith; Manish Gandhi; Evan Farkash; Vijay K Sharma; Milagros Samaniego-Picota; Mark D Stegall Journal: Transpl Int Date: 2019-02-08 Impact factor: 3.782
Authors: Mieko Toyoda; Bong-Ha Shin; Shili Ge; James Mirocha; David Thomas; Maggie Chu; Edgar Rodriguez; Christine Chao; Anna Petrosyan; Odette A Galera; Ashley Vo; Jua Choi; Alice Peng; Joseph Kahwaji; Stanley C Jordan Journal: J Immunol Res Date: 2017-02-06 Impact factor: 4.818
Authors: Darlene Vigil; Nikifor K Konstantinov; Marc Barry; Antonia M Harford; Karen S Servilla; Young Ho Kim; Yijuan Sun; Kavitha Ganta; Antonios H Tzamaloukas Journal: World J Transplant Date: 2016-09-24
Authors: Xingqiang Lai; Xin Zheng; James M Mathew; Lorenzo Gallon; Joseph R Leventhal; Zheng Jenny Zhang Journal: Front Immunol Date: 2021-05-20 Impact factor: 7.561